| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LIDDS Stock Overview
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden.
LIDDS AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr6.86 |
| 52 Week High | kr15.66 |
| 52 Week Low | kr5.70 |
| Beta | 0.64 |
| 1 Month Change | -2.00% |
| 3 Month Change | -7.80% |
| 1 Year Change | -54.14% |
| 3 Year Change | -61.02% |
| 5 Year Change | -40.61% |
| Change since IPO | -37.64% |
Recent News & Updates
Here's Why We're Watching LIDDS' (STO:LIDDS) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Shareholder Returns
| LIDDS | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -3.4% | -1.9% | -0.8% |
| 1Y | -54.1% | -22.8% | -23.9% |
Return vs Industry: LIDDS underperformed the Swedish Biotechs industry which returned -22.1% over the past year.
Return vs Market: LIDDS underperformed the Swedish Market which returned -22% over the past year.
Price Volatility
| LIDDS volatility | |
|---|---|
| LIDDS Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in SE Market | 12.7% |
| 10% least volatile stocks in SE Market | 4.6% |
Stable Share Price: LIDDS is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: LIDDS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 6 | Nina Herne | https://www.liddspharma.com |
LIDDS AB (publ), a pharmaceutical company, develops and sells pharmaceutical products for cancer and other diseases in Sweden. It is developing various drugs, such as NZ-2HOF to treat prostate cancer; NZ-DTX to treat breast, prostate, head, neck, stomach, and lung cancer; NZ-DOX for the treatment of solid tumors; NZ-IO, an immunotherapy; NZ-STING for the treatment of immuno-oncology; and NZ-TLR9 for enhancing cancer immunotherapies. LIDDS AB (publ) has a collaboration agreement with PharmIdea SIA to focus on anti-cancer drugs and sterile formulations.
LIDDS AB (publ) Fundamentals Summary
| LIDDS fundamental statistics | |
|---|---|
| Market Cap | kr238.31m |
| Earnings (TTM) | -kr36.24m |
| Revenue (TTM) | kr3.51m |
68.0x
P/S Ratio-6.6x
P/E RatioIs LIDDS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIDDS income statement (TTM) | |
|---|---|
| Revenue | kr3.51m |
| Cost of Revenue | kr26.70m |
| Gross Profit | -kr23.20m |
| Other Expenses | kr13.04m |
| Earnings | -kr36.24m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 25, 2022
| Earnings per share (EPS) | -1.04 |
| Gross Margin | -661.61% |
| Net Profit Margin | -1,033.54% |
| Debt/Equity Ratio | 0.0% |
How did LIDDS perform over the long term?
See historical performance and comparison